Annual report pursuant to Section 13 and 15(d)

License Acquired (Narrative) (Details)

v3.24.1
License Acquired (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended 24 Months Ended
Sep. 26, 2023
Sep. 08, 2023
Aug. 31, 2023
Apr. 27, 2023
Feb. 28, 2023
Oct. 11, 2022
Jul. 31, 2020
Jun. 30, 2021
Jul. 31, 2020
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones                       $ 500
Expenses recognized                   $ 106,071 $ 134,876  
Research and Development Expense                   $ 106,071 $ 134,876  
Journey | Dr. Reddy's Laboratories, Ltd [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones                 $ 4,000      
Journey | Dr. Reddy's Laboratories, Ltd [Member] | Additional Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones             $ 17,000          
Journey | Maruho Co Ltd                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones     $ 45,000                  
Journey | Maruho Co Ltd | Maruho achieving net sales of ¥4 billion (yen) in single fiscal year                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones     $ 10,000                  
Journey | DFD Agreement | Licensing Agreements [Member] | Dr. Reddy's Laboratories, Ltd [Member] | Achievement of Certain clinical Development, Regulatory and First Commercial Sale milestones [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones               $ 158,000        
Avenue                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Common shares issued (in shares)           3,636,365            
Avenue | AnnJi Pharmaceutical Co                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Royalty Expense   $ 1,000   $ 2,000 $ 3,000              
Common shares issued (in shares)         831,618              
Expenses recognized         $ 900              
Stock offering, price per share         $ 2.10              
Research and Development Expense         $ 900              
Avenue | AnnJi Pharmaceutical Co | Additional Indication Milestones                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Common shares issued (in shares)         276,652              
Expenses recognized $ 300                      
Research and Development Expense $ 300                      
Avenue | AnnJi Pharmaceutical Co | Drug Development Milestones [Member]                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones         $ 27,500              
Avenue | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones         165,000              
Avenue | Minimum | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue Recognition, Milestone Method, Revenue Recognized         75,000              
Avenue | Maximum | AnnJi Pharmaceutical Co | First Indication Milestones                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones         10,800              
Avenue | Maximum | AnnJi Pharmaceutical Co | Additional Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue Recognition, Milestone Method, Revenue Recognized         750,000              
Avenue | Maximum | DFD Agreement | AnnJi Pharmaceutical Co | Additional Indication Milestones                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Payments of milestones         $ 14,500